the company was changed into Jiangsu Kanion Pharmaceutical Co., Ltd.
it became a key enterprise in Lianyungang pharmaceutical industry base of
National Torch Plan.
the company was listed in Shanghai Stock Exchange (stock code: 600557).
a state-level post-doctoral scientific research workstation was established.
a modern TCM research institute of Kanion was founded.
the company applied for FDA’s approval of Guizhifuling capsule.
the company became a national enterprise technology center.
Reduning injection was launched.
a phase IIa clinical study of Guizhifuling capsule was initiated in the USA.
the construction of the National Key Laboratory for New Technologies in TCM
Manufacturing Process was approved.
Kanion became a national well-known trademark.
a phase IIb clinical study of Guizhifuling capsule was initiated in the USA.
the sales volume of Ruduning injection single variety was over RMB 1 billion.
Kanion Modern Chinese Medicine Health Industry Park was constructed. The whole
company moved to the Park (the registration address was changed into: Jiangning Industrial
Town, Lianyungang Economic and Technological Development Zone).
Ginkgo diterpene lactone glucamine injection appeared on the market and was evaluated as “2012 top ten prescription medicine”.
Reduning injection won the 15th Chinese patent gold award.
it was evaluated as a national technological innovation demonstration enterprise and a
national innovation pilot enterprise.
the TCM intelligent extraction and refining factory was constructed and put into service,
and was listed as the only project in the TCM industry by the Ministry of Industry and
Information Technology into the first batch of intelligent manufacturing pilot projects.